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THE PROGNOSTIC ROLE OF VEGF IN HEAD AND NECK SQUAMOUS CELL 
CARCINOMA 
ROHIT MATHEW 
ABSTRACT 
Emerging from potentially malignant disorders that in most cases will never 
become cancerous, head and neck squamous cell carcinoma (HNSCC) is a cancer that is 
extremely difficult to diagnose early.  This late stage diagnosis has allowed limited 
improvements in overall survival (OS) as patients are prone to local recurrence, 
secondary primary tumors, and distant metastasis.  As a result, it has become vitally 
important to assess the prognostic value of biological marker screening to provide an 
avenue for early diagnosis and identification of local recurrence or residual secondary 
tumor sites.  Many characteristic markers such as EGFR, p16, p53 and VEGF that are con
 stitutively mutated in HNSCC have been identified.  However, the dysregulation 
of VEGF marks a landmark mutation that accelerates the diseases progression and 
spread.  An angiogenic protein normally expressed in response to hypoxic conditions, 
VEGF allows the creation of new vasculature to remove catabolites and bestows 
resistance to normal cellular apoptotic signals; pathways often employed by 
chemotherapeutics.  Therefore, early identification of VEGF poses a unique opportunity 
to employ aggressive therapeutic regimens in combination with precision surgical 
resection to eliminate the cancer before neovascualture invasion has occurred and the 
tumor has expanded significantly.  For this reason, this Review will examine the current 
literature available on VEGFs role in HNSCC, its value as a prognostic marker. 
  vii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
ABSTRACT ....................................................................................................................... vi 
TABLE OF CONTENTS .................................................................................................. vii 
LIST OF FIGURES ......................................................................................................... viii 
LIST OF ABBREVIATIONS ............................................................................................ ix 
INTRODUCTION .............................................................................................................. 1 
Epidemiology ............................................................................................................. 4 
Risk Factors ............................................................................................................... 6 
Molecular Progression and Staging ........................................................................ 7 
Treatment and Current Standard of Care ........................................................... 11 
PUBLISHED STUDIES ................................................................................................... 16 
DISCUSSION ................................................................................................................... 20 
VITA ................................................................................................................................. 29 
 
  viii 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Estimated age-standardized oral and pharyngeal 
cancer incidence rates per 100,000 population 
4 
2 Phenotypical histological and molecular progression of 
head and neck squamous cell carcinoma 
9 
3 Induction of survivin mediates the integrity of the 
microtubule network in the presence of VEGF in 
HUVECs 
19 
   
   
   
  
  ix 
LIST OF ABBREVIATIONS 
 
BU ............................................................................................................ Boston University 
bFGF .................................................................................... basic Fibroblast Growth Factor 
CCRT .................................................................................. Concurrent Chemoradiotherapy 
CDDP ...................................................................................................................... Cisplatin 
CRT ........................................................................................................ Chemoradiotherapy 
CSCs ........................................................................................................ Cancer Stem Cells 
EGFR ............................................................................ Epidermal Growth Factor Receptor 
FA ............................................................................................................... Fanconi Anemia 
HER.................................................................. Human Epidermal Growth Factor Receptor 
HNSCC ............................................................. Head and Neck Squamous Cell Carcinoma 
HUVEC ................................................................. Human Umbilical Vein Endothelial Cell 
IC.................................................................................................... Induction Chemotherapy 
LOH ................................................................................................. Loss of Heterozygosity 
MSCTR ............................................... Mazumdar Shaw Center for Translational Research 
OS ............................................................................................................... Overall Survival 
PI3K ............................................................................................Phosphoinositide 3-Kinase 
PKB ............................................................................................................ Protein Kinase B 
PMDs ................................................................................. Potentially Malignant Disorders 
QOL ...............................................................................................................Quality of Life 
R/M ........................................................................................... Recurrent and/or Metastatic 
RT .................................................................................................................... Radiotherapy 
  x 
TKR.............................................................................................. Tyrosine Kinase Receptor 
VBL..................................................................................................................... Vinblastine 
 1 
INTRODUCTION 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common 
cancer in world and collectively refers to the aggressive malignant neoplasms that 
manifest themselves in the epithelial lining of the oral cavity, oropharynx, larynx or 
hypopharynx (Abou-Elhamd & Habib, 2008; Kamangar, Dores, & Anderson, 2006).  
Patients are often diagnosed at advanced stages of the disease with a discernible 
primary site and a palpable mass.  Depending on the location of the tumor, 
symptoms may include dysphagia, hoarseness, odynophagia, and sore throat 
(Haddad & Shin, 2008).  Typically, most patients range from 60-70 years in age 
however, a small portion of patients have presented under 45 years of age.  Though 
other cancers also occur in these anatomical regions, they make up a smaller 
percentage of registered cases, are classified and assessed differently, and therefore 
are not considered here. 
HNSCC is a particularly notorious malignancy.  Historically, patients have 
been treated using disfiguring surgical resection followed by radiotherapy.  Such 
treatment has frequently been accompanied by loss of organ function and decreased 
quality of life (QOL).  In the case of recurrent or metastatic (R/M) HSNCC additional 
platinum based regimens are employed with some limited response.  Unfortunately, 
little gain in overall survival (OS) has been observed, and platinum based 
treatments are associated with significant added toxicity, which dramatically reduce 
patient tolerance and QOL (Sacco & Cohen, 2015).  
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Recent improvements in technology and research have yielded a better 
understanding of HNSCC and its biological characteristics, which has ushered in new 
options for treatment and therapy.  However, despite these advances the OS 
remains at 50% over five years; a rather daunting figure (Forastiere, Koch, Trotti, & 
Sidransky, 2001; Leemans, Braakhuis, & Brakenhoff, 2011). 
With seemingly little improvement in OS made, it is extremely important to 
understand the factors that contribute to this poor prognosis and what drives them.  
Difficulty in diagnosing HNSCC during its emergent stages is primarily 
responsible for high mortality rates.  Approximately two thirds of patients present 
at advanced stages.  At this point the disease has already affected the regional lymph 
nodes, making recurrences common, and reducing chances of recovery (Argiris, 
Karamouzis, Raben, & Ferris, 2008).  Presenting at such advanced stages requires 
far more aggressive treatments and limits positive outcomes.  Therefore, as with all 
lifestyle cancers, the most effective treatment in the absence of outright abstinence 
is early-detection and screening for patient populations with known risk factors. 
  In addition, once diagnosed the aggressive therapies associated with late 
stage identification incur significant financial costs; this coupled with the more 
effective larger doses leading to toxicity and patient intolerance, regimens are often 
discontinued prematurely. Furthermore, aggressive chemotherapeutics have made 
little headway in OS, often yielding little to no delay in disease progression and 
substantially decreasing QOL. 
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An additional consideration that contributes significantly to poor OS is 
recurrence.  Recurrence is a consistent concern when treating late stage cancer and 
is especially prevalent among HNSCC cases.  One of the modes of recurrence 
development is the result of tumor cells entering the vasculature implanting in 
other regions either within the same organ or beyond (in which case, it is termed 
metastasis).  Recently, studies have identified a small sub-population of cells, cancer 
stem cells (CSCs), that may contribute significantly to recurrence by acting as 
tumor-progenitor cells (Prince et al., 2007).  These cells seem to play a significant 
role in tumor recurrence and metastasis, which in turn drive high morbidity and 
mortality. 
Finally, HNSCC commonly develops resistance.  Thus, once diagnosed 
patients still run the risk of their cancer developing resistance to the therapeutics 
being used to treat it, lowering their efficacy.  To combat this, practitioners often 
advocate for aggressive treatments that reduce the likelihood of resistance 
developing, however, increased toxicity causes patients to prematurely discontinue 
the cycle.  Resistance, significantly reduces treatment options.  In recent years, 
doctors have started to employ combinatorial therapies that mount a multi-front 
attack, however, resistance can still occur. 
The current standard of care, typically poor prognosis, and significant 
decrease in QOL, make examination and screening for changes to biological markers 
like VEGF of particular importance as it marks a profound shift in the lethality of the 
disease.  Determining if VEGF is overexpressed by in vivo patient tumors can 
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provide invaluable foundational knowledge allowing doctors and patients to select 
the best course of treatment.  Based on this knowledge, patients can decide to 
salvage QOL when associated resistance is present, or pursue curative treatment in 
its absence. 
 
Epidemiology 
In 2008 HNSCC amassed ~500,000 new cases and was responsible for 
~273,000 deaths.  However, it is unlikely these numbers are representative of 
HNSCCs global distribution.  HNSCC exhibits remarkable geographical variation; two 
thirds of cases documented occur in developing nations (Ferlay et al., 2010). 
   
Figure 1: Estimated age-standardized oral and pharyngeal cancer incidence 
rates per 100,000 population.  The top map shows data for males while the 
bottom map shows data for females.  These maps highlight the marked geographic 
variation associated with HNSCC. (Johnson & Jayasekara, 2011) 
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Incidence is influenced by a number of exogenous factors, endogenous 
susceptibility, and access to quality care, while mortality is influenced largely by 
staging of cancer at presentation and individual response to therapy (Kamangar et 
al., 2006). 
It is important to consider inherent biases when analyzing the 
epidemiological data associated with HNSCC.  Information pertaining to a cancer 
that primarily affects those in underdeveloped nations is often poorly documented 
or not available at all.  Additionally, information gathering related to cancer 
incidence is performed by cancer registries, which in turn introduces bias as only 
the patients that are able to make the journey to hospitals which have registries are 
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documented.  For example, in regions of rural India where access to hospital-based 
cancer registries is scarce, difficulty following up, and lack of death certification 
requirement, suggests the incidence might be significantly higher than reported 
(Johnson & Jayasekara, 2011).  HNSCC’s disposition towards underdeveloped 
nations and high costs associated with therapeutic regiments warrants the 
investigation of explorative diagnostics that afford informed treatment decisions. 
 
Risk Factors 
Factors that contribute to the rise of HNSCC are well known and have been 
documented extensively.  HNSCC is predominantly a lifestyle cancer; largely self-
induced, with external factors such as tobacco, betel quid, alcohol, poor fruit and 
vegetable consumption, although other contributing factors such as HPV are well 
documented. The consumption of alcohol in parallel with smoking has a synergistic 
effect, increasing the risk of cancer exponentially (Elango, Gangadharan, Sumithra, & 
Kuriakose, 2006; Farshadpour, Hordijk, & Koole, 2008; Petti, 2009; Sturgis & 
Cinciripini, 2007; Vineis, Alavanja, & Buffler, 2004).  In addition, recent studies have 
shown that inherent endogenous susceptibilities and genetic disorders such as 
Fanconi Anemia (FA) also contribute to the incidence of HNSCC. (Cloos et al., 1996; 
Kutler et al., 2003; Suárez, Rodrigo, Ferlito, & Cabanillas, 2006). 
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Molecular Progression and Staging 
 Cancer arises as an aggregation of genomic aberrations (D. Hanahan & 
Weinberg, 2000).  With this is in mind significant effort has been devoted to 
understanding the alterations that take place as a cell undergoes malignant 
transformation.  Advancements in molecular analysis techniques have allowed the 
identification of markers that function in a number of cellular functions such as 
growth, proliferation, communication, and death.  This knowledge has provided 
immense insight into how the dysregulation or activation of these molecules play a 
role in cancer biology. 
Cancer is inherently the result of a series of mutations conferring either a 
gain-of-function activation of an oncogene or a loss-of-function knockout of a tumor 
suppression gene.  In order for malignant transformation to occur a cell must have 
acquired enough of the following:  rate-limiting mutations, self-stimulation of 
growth, resistance to inhibitory signaling, resistance to programmed cell death, 
indefinite regeneration, stimulation of vascular growth, and local tissue invasion.  
These traits, originally described by Weinberg and Hanahan, have since been 
revised to include the presence of abnormal metabolic pathways and immune 
system evasion (D. Hanahan & Weinberg, 2000; Douglas Hanahan & Weinberg, 
2011). 
 Like many other cancers borne of lifestyle choices, HNSCC is usually age 
dependent; stochastically acquiring mutations, until it has accumulated sufficient 
rate-limiting mutations to cause malignancy.  The apical squamous epithelial cells of 
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the aero-digestive mucosal lining affected in HNSCC are particularly susceptible to 
these mutations due to their exposure to environmental carcinogens and their 
highly replicative nature necessitated by this contact. 
 
Potentially Malignant Disorders 
HNSCC progresses in two discernable stages, appearance of white or red 
patches on the interior of the oral cavity and development of a frank carcinoma.  
There have been several attempts over the years to unify the nomenclature used to 
clinically define the lesions or irregularities of the oral mucosa.  The most recent 
evaluation proposed the term potentially malignant disorder (PMD) to describe a 
‘family of morphological alterations amongst which some may have an increased 
potential for malignant transformation’ (Warnakulasuriya, Johnson, & van der Waal, 
2007).  It is important to note that a potentially malignant disorder conveys a caveat 
to identification and classification of these abnormal patches as precancerous; many 
of these will never become cancerous.  Thus, accurate identification largely depends 
on testing of biopsies to accurately diagnose that malignant disorder.  PMDs include 
a number of disorders, however, we will focus on leukoplakia, the PMD that most 
commonly undergoes transformation to HNSCC.  Leukoplakia can be clinically 
categorized into two types, homogenous and heterogeneous.  Homogenous 
leukoplakia is defined as a white lesion with a flat, thin appearance which may 
exhibit shallow cracks, and has a smooth, wrinkled or corrugated surface with 
consistent texture (Axéll, Pindborg, Smith, van der Waal, & an International 
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Collaborative Group on Oral White, 1996). Heterogeneous leukoplakia has been 
identified as a white or white and red lesion (erythroplakia) that is irregularly flat, 
nodular, or verrucous.  Heterogeneous leukoplakia is far more aggressive than other 
type of oral leukoplakia, progressing in three stages inexorably from its nascent 
stage to squamous cell carcinoma (Batsakis, Suarez, & El-Naggar, 1999).  The 
transition from PMD to frank carcinoma is marked by a number of chromosomal 
aberrations constitutively present at key histological presentations as shown in 
Figure 2.  Critical mutations such as those to p16, p53, and VEGF confer many of 
required traits described by Hanahan and Weinberg in 2000.  Mutations to VEGF(R) 
and FGF(R) typically occur in the late stages of the disease, are linked with 
invasive/metastatic carcinoma, and are prognostic markers associated with 
resistance to conventional cytotoxic chemotherapeutics. 
 
Figure 2: Phenotypical histological and molecular multi-step progression from 
normal to frank head and neck squamous cell carcinoma. (Haddad & Shin, 2008) 
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p53 
In general, loss of function of tumor suppressor genes is the most common 
pathway to tumorigenesis.  p53, the most commonly mutated tumor suppressor 
gene in human cancers, is responsible for arresting cellular growth, repairing 
damaged DNA and cellular death.  In HNSCC, studies have shown that p53 is 
mutated in ~50% of all patient tumors with significantly higher alteration in 
invasive HNSCC (43%) than in PMDs (16%) suggesting involvement early in 
malignant transformation (Boyle, Hakim, Koch, van der Riet, & Hruban, 1993). 
 
p16 
Another tumor suppressor gene, p16, responsible for slowing the cellular 
progression from G1 phase to the S phase by inhibiting cyclin dependent kinase is 
also found to be inactivated in later stages of tumor progression.  IHC analysis of in-
situ tumors has also demonstrated  that p16 is also inactivated with high frequency 
in head neck squamous cell carcinoma (Reed et al., 1996).  Though specific 
mechanisms for its inactivation still require further investigation. 
 
Chromosomal Region 9p21 
Loss of heterozygosity (LOH), epigenetic methylation or outright deletion on 
chromosomes are key in many tumor types.  The INK4a-ARF (CDKN2A) locus which 
encodes two tumor suppressor genes, p14ARF and p16INK4a, is located on 
chromosome 9p21.  These two distinct genes mark the convergence of the p53 and 
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Rb tumor suppressive pathways. Studies have found LOH at 9p21-22 in 72% of 
informative tumors with somatic mutations and methylation of the p16ARF promoter 
region at the INK4a-ARF locus occurring frequently in both malignant and benign 
tumors (van der Riet et al., 1994; Weber, Wittekind, & Tannapfel, 2003).   
 
Treatment and Current Standard of Care 
Most patients (66%) that are diagnosed with HNSCC usually present with 
locally advanced, stage III or stage IV malignancies that usually require multi-modal 
therapy consisting of chemotherapy, radiotherapy, and surgical resection.  Surgery 
and radiotherapy (RT) have been the mainstays of therapy for HNSCC, yielding OS 
rates ranging from 10%-40% (Vokes, Weichselbaum, Lippman, & Hong, 1993).  If 
patients present with early stages of the disease (stage I, stage II) single-modality 
therapy, either radiation or surgical resection alone, is sufficient and offers better 
outcomes.  Though in these early disease cases the prognosis is good, local and 
regional disease recurrence takes place in approximately 30% of patients and 
distant metastasis appears in 25%, therefore many of these patients are still at risk 
and must be closely monitored (Cooper, Pajak, & Forastiere, 2004; Pillsbury & Clark, 
1997). 
 
Surgical Resection 
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  Invasive surgery is always challenging; this is ever more true when it 
involves the head and neck owing to the immense anatomical complexity.  
Preservation of structure and function when considering treatments options should 
always be of foremost concern; achieving these goals though is a challenge as both 
the disease and treatment affect major surrounding vessels.  Historically, despite the 
facial mutilation that often accompanied it, surgery has been preferentially favored 
due to the decreased likelihood for post-operative metastasis.  However, in recent 
years, surgical techniques have vastly improved and with them so too have 
prognoses.  Minimally invasive keyhole surgeries and multi-modal imaging 
techniques in conjunction with advances in reconstructive surgery have provided 
better aesthetic, functional, and clinical outcomes across the board (D'Cruz et al., 
2015; Sadick, Schoenberg, Hoermann, & Sadick, 2012; Urken, 2003).  Employing 
these novel methods and the wealth or pre-operative information, surgeons are able 
to avoid performing the mutilating resections that used to be commonplace and 
patients no longer face the daunting prospect of perpetual disfigurement.  
Unfortunately, with so much emphasis placed on surgical skill and resources, 
surgical outcomes vary widely depending greatly on the treatment center’s facilities 
and level of experience. 
 
Chemotherapy 
 Advances in treatment have not been isolated to surgery alone, 
chemotherapy, radiation therapy (RT), and targeted molecular therapies have 
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evolved immensely in parallel.  Chemotherapy, the backbone of the locally advanced 
disease treatment regimen, is now commonly administered concurrently or prior to 
radiation.  Induction chemotherapy (IC), the administration of chemotherapeutic 
agents (generally cisplatin and fluorouracil) prior to RT, has been studied for many 
years.  Despite OS remaining the same, some evidence suggest that IC offers 
improved organ preservation, reduced metastasis, and overall benefit to 
locoregional control and thus remains a common treatment therapy for advanced 
HNSCC (Harari, 1997; Ock et al., 2016).  Typically, tumors shrink drastically in 
response to chemotherapy; therefore, IC is utilized to reduce tumor size prior to 
surgery or RT with the intention to reduce surgical invasiveness or increased 
toxicity.  More recently, concurrent chemoradiotherapy (CCRT) has found use as an 
alternative to surgical resection, however, it can also be performed post-operatively 
(adjuvant chemoradiation), if a patient has increased likelihood for recurrence.  
CCRT delivers chemotherapy concomitantly with radiation and has been widely 
adopted as the primary treatment for a variety of solid tumors.  Though schedule 
optimization and agent interactions are still under investigation its use has yielded 
promising results.  In HNSCC, CCRT has shown to improve overall 5-year survival by 
approximately 8% in comparison to RT alone and in high-risk post-operative 
patients significantly improves the rates of local and regional control and disease-
free survival despite the associated adverse effects (Brizel et al., 1998; Cooper et al., 
2004; Pignon, Bourhis, Domenge, & Designé, 2000; Zhang et al., 2010). 
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Radiation Therapy 
Fractionation RT, the process by which the total radiation dose is divided 
among several smaller doses administered over a period of days, is employed in the 
treatment of multiple cancers and has shown to decrease the toxic side effects on 
the surrounding healthy cells (Ghita et al., 2016).  This has improved overall patient 
tolerance and therapy success.  Fractionation schedules vary; a common schedule 
may divide a dose into 30 units over the course of 5 to 6 weeks.  As technology 
continues to evolve, conventional fractionation continues to be challenged by 
interval and dose varying strategies such as hypofractionation and 
hyperfractionation.  Hypofractionation, an amplified version of fractionation RT that 
delivers higher doses of radiation in a shorter duration of time is currently 
undergoing evaluation due to its convenience and decreased financial burden.   
While research continues to be done, moderately hypofractionated therapy is likely 
to become the standard treatment for many cancers (Koulis, Phan, & Olivotto, 2015; 
Wilkins et al., 2015).   
Another advancement in RT, intensity-modulated radiation (IMRT) enables 
the precise delivery of RT to the tumor by conforming the dose to the three 
dimensional shape of the tumor while sparing the surrounding healthy cells (Deloch 
et al., 2016). Modulating the intensity of the radiation beam to target the tumor 
alone has also improved outcomes significantly specifically in complex anatomical 
regions such as the head and neck (Al-Mamgani et al., 2015). 
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Targeted Therapies 
Finally, as our understanding of molecular biology and cancers biological 
mechanisms have grown, molecular targeted therapies have arisen.  Monoclonal 
antibodies (mAb), molecules that bind to an extracellular epitope, have come to the 
forefront of cancer treatment regimens as a means to specifically inhibit certain 
problematic signaling pathways.  Cetuximab, one of the mAbs approved for use in 
the treatment of HNSCC, is a chimeric mouse-human model that functions by 
binding to EGFR and turning off uncontrolled growth signaling.  The use for 
Cetuximab is supported by EGFR overexpression in 80% to 90% HNSCC tumors and 
there is evidence to suggest that this occurs as a result of gene amplification 
(Nagatsuka, Ishiwari, Tsujigiwa, Nakano, & Nagai, 2001).   
 
Investigation of Genetic Markers 
 Ultimately, the current state of HNSCC offers little hope to those it affects.  
The treatments available are aggressive, painful and at their culmination offer little 
by way of success. Furthermore, options for early diagnoses are limited as patients 
only present once the cancer has progressed to the point that it is noticeable.  For 
these reasons, it is critical that we investigate genetic markers such as VEGF that are 
constitutively mutated throughout the patient population to identify their value as 
prognostic markers and potential inclusion in diagnostic panels. 
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PUBLISHED STUDIES 
  
Vascular endothelial growth factor (VEGF) is a protein that binds to a family 
of tyrosine kinase receptors (TKRs) known as vascular endothelial growth factor 
receptors (VEGFR) on the cell surface promoting angiogenesis. Numerous studies 
have found that VEGF is critically expressed during embryogenesis in order to 
develop the vascular supply.  Throughout adult life VEGF is tightly regulated; it is 
expressed during wound healing, muscle growth, and during reproductive function.  
Angiogenic proteins are primarily stimulated by hypoxic cellular conditions and 
function to return oxygen to these tissues by encouraging proliferation, 
differentiation, and migration of vascular endothelial cells and increasing capillary 
permeability (Breslin, Pappas, & Cerveira, 2003; Ferrara & Davis-Smyth, 1997). 
A number of pathologies advantageously overexpress VEGF.  In proliferative 
retinopathies and age-related macular degeneration, the expression of VEGF is the 
primary disease-causing agent leading to leakage, bleeding, clot formation and 
fibrosis.  In cancer, however, VEGF plays a supporting role, allowing solid tumors to 
overcome the growth limitations imposed by their environment’s current-state 
vasculature.  Furthermore, the immature basement membranes of the budding 
vessels are far more pliable providing tumor cells with an opportunity for 
vasculature invasion and distant metastasis (Mineta et al., 2000; Sauter, Nesbit, 
Watson, & Klein-Szanto…, 1999). VEGF expression also prevents cellular apoptosis 
pathways, which has been linked to increased resistance to certain therapeutics 
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(Gupta, Kshirsagar, Li, & Gui, 1999; Tran, Master, Joanne, & Rak, 2002).  As a result, 
VEGF expression marks a key transition point in the progress of the cancer strongly 
indicating a poor prognosis due to its association with increased lymph-node 
spread, subsequently lowered OS, and increased risk of chemoresistance (Mineta et 
al., 2000). 
The value of VEGF as prognostic marker has been demonstrated time and 
again in a number of cancers.  However, it’s value to HNSCC was identified in a meta-
analysis study performed in 2005 (Kyzas, Cunha, & Ioannidis, 2005).  The study not 
only identified an association between VEGF overexpression and mortality but also 
highlighted a more limited association with lymph node metastasis.  After a filtering 
process the investigators ultimately identified 17 studies (n =1,287 patients) eligible 
for inclusion in the meta-analyses eight from Japan, eight from Europe, and one from 
the United States. In each study, VEGF measurements had been taken in patients 
with HNSCC.  The selected studies all had taken measurements at the primary site 
prior to the administration of chemotherapy or radiation.  Of the seventeen studies 
that were eligible, twelve studies (n =1,002 patients) contained data on 2-year 
survival that could be obtained from published or corresponded information.  Of the 
seventeen studies, five studies (n =285 patients) contained only lymph node status 
data, while six of the twelve studies that contained 2-year OS (n =437 patients) 
contained data on lymph node status as well.  Ultimately eleven studies (n = 722 
patients) were analyzed for the status of lymph nodes.  Across the eligible studies 
the reported median age of the patients ranged from 58 – 71 years of age.  The meta-
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analysis identified significant association between prognosis and VEGF 
overexpression.  Mortality was found to be 1.88-fold higher in VEGF positive 
patients.  Moreover, the study also loosely identified an association between lymph 
node metastasis and VEGF expression, however, the result was not statistically 
significant. 
A study performed in 2001 illustrated the protective role of both basic 
fibroblast growth factor (bFGF) and VEGF by epigenetically inducing drug resistance 
in human umbilical vein endothelial cells (HUVECs) (Tran et al., 2002). This study 
demonstrated that the PI3K and PKB activation are critical for VEGF mediated 
chemoresistance, by selectively inhibiting/activating each pathway to identify if 
cells remained resistant.  In addition, the induction of anti-apoptotic protein 
survivin was also examined.  As shown in other similar studies survivin levels were 
upregulated 10 to 20-fold in VEGF stimulated cells and these levels remained the 
same in the presence of chemotherapy (Taxol and Vinblastine (VBL)).  Of note, PI3K 
activity was required for VEGF-mediated induction of survivin and bFGF also 
induced a 10 to 20-fold increase in survivin expression.  Noticing that survivin 
protein levels remained high in the presence of disrupting microtubule drugs such 
as Vinblastine and Taxol, Tran et al., further analyzed the role survivin played on 
microtubule structure.  They found that in the absence of VEGF untreated cells and 
those treated with either CDDP or Taxol all appeared to have a similar rounded 
morphology with little microtubule organization (Figure 2; a, c, e).  In contrast, cells 
grown in the presence of VEGF (+) display an elongated structure and were spread 
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out (Figure 2; b). The same healthy elongated morphology similar to that of the 
growing cells were observed for cells in the presence of VEGF and the presence of 
CDDP and Taxol (Figure 2; d, f).  Based on this it is clear that VEGF is a mediator of 
microtubule integrity.  To further test survivin’s role as the key agent conferring 
chemoresistance, HUVECs were retrovirally infected with an empty vector or wild-
type survivin.  The cells retrovirally infected with wild-type surviving display a 
similar healthy morphology as those treated with VEGF in the presence of CDDP and 
Taxol (Figure 2; h, i, j).  Tran et al., concluded that survivin, a rate-limiting regulator 
of apoptotic threshold, is a primary mediator of VEGF chemoresistance promoting 
preservation of cellular integrity in the presence of chemotherapeutic drugs (Tran 
et al., 2002). 
 
Figure 3: Induction of survivin mediates the integrity of the microtubule 
network in the presence of VEGF in HUVECs.  HUVECs were stained for -tubulin 
and grown in the presence of VEGF and with or without drug.   (Tran et al., 2002)   
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DISCUSSION 
 
VEGF plays a vital and irreplaceable role in the body; one that HNSCC and 
many other cancers takes advantage of to proliferate and expand.  Based on our 
current understanding it is clear that the investigation of biological markers, such as 
VEGF, as indicators of prognosis has significant therapeutic value.  While VEGF’s 
role as a prognostic marker in multiple neoplastic cancers has been known for some 
time, it has not yet found ubiquitous adoption as a tool to inform therapeutic 
decisions taken by patients and their doctors. 
For lifestyle cancers, such as HNSCC, the most successful and obvious 
curative method is, of course, prevention through abstinence of risk factors.  
However, in lieu of this it is critical that we employ the recognizable pattern of 
mutations that lead up to outright carcinoma by adopting early-detection screening.  
Early-detection screening for known at-risk patients will likely have a profound 
effect on the OS for HNSCC, which currently remains steady at approximately five 
years.  Close monitoring of patients in the pre-malignant stages of the cancer will 
allow far earlier detection, less invasive surgical procedures, less aggressive 
therapeutic regimens and likely will drive OS up. 
VEGF upregulation marks a critical transition point in the progression of 
HNSCC indicating that research dollars should be allocated to the identification and 
detection of VEGF and other mutations occurring prior to its dysregulation; most 
importantly those that occur during the transition from severe dysplasia to 
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carcinoma in-situ.  While current research has identified a preliminary pattern of 
mutations that lead up to outright carcinoma a clear panel of markers and their 
correlated staging remains to be created.  As a diagnostic tool this offers a promising 
low-cost solution to inform HNSCC therapy decisions in the third world nations in 
which it is most prevalent. 
Moving forward it is important that care decisions leverage information 
garnered from early-detection screening and marker panels.  As technology and 
medical innovation usher in a new era of low-cost, efficient, connected, personalized 
healthcare it is critical that practitioners augment their practices to account for 
these advances.  This new paradigm for personalized treatment curtailed to the 
specific characteristics of an individual’s disease offers patients the ability to take 
ownership in their own care.  Ultimately, we enable patients to dictate the narrative 
of their own lives, whether it be to pursue curative treatment or to live out the 
remainder of their days in the comfort of their own homes. 
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